Goldman Sachs’s Artiva Biotherapeutics ARTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.08M Buy
151,457
+135,677
+860% +$1.37M ﹤0.01% 5176
2026
Q2
$153K Buy
15,780
+4,315
+38% +$39.3K ﹤0.01% 6267
2026
Q1
$73.8K Sell
11,465
-595
-5% -$2.94K ﹤0.01% 6247
2025
Q4
$51.7K Sell
12,060
-37,717
-76% -$142K ﹤0.01% 6284
2025
Q3
$143K Sell
49,777
-68,226
-58% -$183K ﹤0.01% 6014
2025
Q2
$178K Buy
118,003
+76,051
+181% +$160K ﹤0.01% 5692
2025
Q1
$126K Buy
41,952
+3,882
+10% +$21K ﹤0.01% 5740
2024
Q4
$384K Buy
38,070
+8,523
+29% +$102K ﹤0.01% 5384
2024
Q3
$457K Buy
+29,547
New +$342K ﹤0.01% 5098

Other funds holding ARTV

Goldman Sachs's ARTV Position: Q3 2026 in Review

Goldman Sachs increased its Artiva Biotherapeutics (ARTV) stake by 860% in Q3 2026, buying an estimated $1.37M and bringing the position to 151,457 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5176.

Goldman Sachs first reported a position in ARTV in Q3 2024 and has held it in 9 quarters since. 98 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Goldman Sachs held 151,457 shares of Artiva Biotherapeutics worth $1.08M as of Q3 2026.
  • Goldman Sachs bought 135,677 Artiva Biotherapeutics shares in Q3 2026, an estimated $1.37M.
  • Artiva Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5176 holding.
  • Goldman Sachs first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 9 quarters since.
  • 98 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.